Data Insights
How did the pharmaceutical industry treat orphan designated drugs in Q4 2023 filings?
The global pharmaceutical industry experienced a 5% rise in company filings mentions of orphan designated drugs in Q4 2023 compared...
Q4 2023 update: orphan designated drugs related private equity activity in the pharmaceutical industry
Analysis of the key themes driving private equity deal activity reveals that orphan designated drugs accounted for 5 pharmaceutical deals...
Q4 2023 update: orphan designated drugs related M&A activity in the pharmaceutical industry
Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 30 pharmaceutical deals announced in...
Q3 2023 update: orphan designated drugs related private equity activity in the pharmaceutical industry
Analysis of the key themes driving private equity deal activity reveals that orphan designated drugs accounted for 4 pharmaceutical deals...
Who’s posting what? Orphan Designated Drugs related social media posts increased by 9% in the pharma industry in Q1 2023
The global pharma industry experienced a 9% rise in social media posts on orphan designated drugs in Q1 2023 compared...
Q3 2023 update: orphan designated drugs related M&A activity in the pharmaceutical industry
Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 34 pharmaceutical deals announced in...
How did the pharmaceutical industry treat orphan designated drugs in Q3 2023 filings?
The global pharmaceutical industry experienced a 1% drop in company filings mentions of orphan designated drugs in Q3 2023 compared...